Advance Science, Don't Pressure US FDA On Approvals, Chief Tells Patient Advocates
This article was originally published in SRA
Executive Summary
"Patient advocacy groups should be in the business of advocating for patients, not advocating for specific drugs or development programs," Janet Woodcock, director of the US Foo and Drug Administration's Center for Drug Evaluation and Research (CDER), said at the Biotechnology Industry Organization's 2015 Patient and Health Advocacy Summit in Washington.